Success Story: Rapid EB1A Approval in 19 Days for a Translational Medicine Specialist From China with Our Expert Guidance
Client’s Testimonial:
"Great news! Thanks so much!"
On January 27th, 2026, we received another EB-1A (Alien of Extraordinary Ability) approval for a Fellow Physician in the Field of Medicine (Approval Notice).
General Field: Medicine
Position at the Time of Case Filing: Fellow Physician
Country of Origin: China
State of Residence at the Time of Filing: Arizona
Approval Notice Date: January 27th, 2026
Processing Time: 19 days (Premium Processing Requested)
Case Summary:
Large-scale, evidence-based healthcare improvements often depend on research that turns complex clinical data into findings that clinicians and health systems can act on. In this EB1A case, the client built a focused record in translational medicine by investigating high-impact questions in digestive disease burden, including how disease trends and disparities shape outcomes and resource needs. We organized the petition around this practical relevance, showing how the client’s work supports more informed decision-making in population health and clinical care.
With a B.Med. and an M.Sc. in Otolaryngology, the client developed a strong technical foundation for outcomes and disease-burden research. At the time of filing, the client held a research position at a leading U.S. medical institution and contributed to hypothesis-driven clinical and outcomes studies within pulmonary and critical care, experience that reinforced both the medical grounding and the real-world applicability of the client’s translational work.
The petition presented measurable indicators of independent reliance while also explaining how adjudicators typically interpret these metrics in an EB1A context. The client had authored 23 peer-reviewed journal articles (including 5 first-authored) and 66 abstracts (including 18 first-authored). Rather than treating publication volume as self-proving, we emphasized selectivity and field uptake. The case further emphasized that independent bibliometric analysis placed the client among the top 1% most highly cited authors publishing in translational medicine over the past decade, which we framed as evidence of sustained, field-wide reliance rather than a numbers-only argument.
Peer trust also extended beyond citations. The client had completed at least 14 peer reviews, which we presented as a credibility marker showing that journals relied on the client’s judgment to evaluate others’ research in closely aligned areas.
To reinforce the record, the petition included 6 letters of recommendation from experts familiar with the client’s contributions and their downstream impact.
With the evidence organized around originality, independent reliance, and peer trust, the client’s EB1A petition was approved in 19 days under Premium Processing. We congratulate the client on this outstanding result and look forward to the client’s continued contributions to translational research that strengthens evidence-based healthcare.